ArticleCell biochemistry and biophysics2025
Mimulone-induced Apoptosis through the Extrinsic Pathway and ERK Inactivation in Human Hepatoma Hep3B Cells.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the anticancer effects and the underlying molecular mechanisms of Mimulone on human hepatoma Hep3B cells. Mimulone was found to inhibit cell proliferation and induce apoptosis in Hep3B cells, as demonstrated by annexin V-fluorescein isothiocyanate staining and flow cytometry analyses. Western blot analysis revealed that Mimulone treatment decreased the levels of procaspase-3 and PARP, while increasing the levels of cleaved caspase-3, -8, PARP, Fas, FasL, and FADD. These results suggest that Mimulone induces apoptotic cell death through the activation of the death receptor-mediated (extrinsic) pathway. Furthermore, Mimulone inactivated the extracellular signal-regulated kinase (ERK) and Akt signaling pathways, further enhancing its pro-apoptotic effects. These findings indicate that Mimulone has potential as a therapeutic agent targeting apoptosis and survival signaling pathways in hepatocellular carcinoma cells.
Indexed as
Identifiers
40736885What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.